Damijan Eržen

1.4k total citations
27 papers, 308 citations indexed

About

Damijan Eržen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Damijan Eržen has authored 27 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 6 papers in Physiology. Recurrent topics in Damijan Eržen's work include Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers), Immune Response and Inflammation (5 papers) and Cancer Research and Treatments (4 papers). Damijan Eržen is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (9 papers), Immune Response and Inflammation (5 papers) and Cancer Research and Treatments (4 papers). Damijan Eržen collaborates with scholars based in Canada, Germany and United States. Damijan Eržen's co-authors include Thierry Troosters, Jean Bourbeau, Alan Hamilton, François Maltais, Jure Manfreda, Nicholas R. Anthonisen, Leslíe L. Roos, Nancy Kline Leidy, Lawrence Korducki and Maria Sedeno and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Damijan Eržen

25 papers receiving 299 citations

Peers

Countries citing papers authored by Damijan Eržen

Since Specialization

Citations

This map shows the geographic impact of Damijan Eržen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damijan Eržen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damijan Eržen more than expected).

Fields of papers citing papers by Damijan Eržen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Damijan Eržen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damijan Eržen. The network helps show where Damijan Eržen may publish in the future.

Co-authorship network of co-authors of Damijan Eržen

This figure shows the co-authorship network connecting the top 25 collaborators of Damijan Eržen. A scholar is included among the top collaborators of Damijan Eržen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Damijan Eržen. Damijan Eržen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers 2025 ·Future Oncology ·Sara A. Hurvitz, Matteo Simonelli, Ramón Yarza, David Berz, Shigehisa Kitano, (unknown), (unknown), (unknown), (unknown), Damijan Eržen, (unknown), Giuseppe Curigliano, (unknown), Min Yan, Qingyuan Zhang, Xian Wang, Izuma Nakayama, Kohei Shitara	0
2	Beamion BCGC-1: A phase Ib/II trial of the HER2-selective tyrosine kinase inhibitor (TKI) zongertinib (BI 1810631) + trastuzumab deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1) for patients with metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC). 2025 ·Journal of Clinical Oncology ·Izuma Nakayama, David Berz, (unknown), Damijan Eržen, Kohei Shitara	3
3	Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors 2023 ·Cancer Chemotherapy and Pharmacology ·Noboru Yamamoto, Takafumi Koyama, Toshio Shimizu, (unknown), Takeshi Kawakami, Damijan Eržen, Akiko Sarashina, Bin Li, (unknown), Kentaro Yamazaki	6
4	Mechanisms associated with increased physical activity in patients undergoing self-management behaviour modification in the randomised PHYSACTO trial 2021 ·ERJ Open Research ·Jean Bourbeau, Maria Sedeno, Pei Zhi Li, Thierry Troosters, Alan Hamilton, (unknown), François Maltais, Damijan Eržen, Kim Lavoie	7
5	Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody. 2021 ·Journal of Clinical Oncology ·Maen Hussein, Johanna C. Bendell, Hendrik‐Tobias Arkenau, Quincy S. Chu, Aaron R. Hansen, Damijan Eržen, Zhichao Sun, (unknown), Ivor Percent	2
6	Validity and responsiveness of the Daily- and Clinical visit-PROactive Physical Activity in COPD (D-PPAC and C-PPAC) instruments 2021 ·Thorax ·Judith García‐Aymerich, Milo A. Puhan, Solange Corriol‐Rohou, Corina de Jong, Heleen Demeyer, Fabienne Dobbels, Damijan Eržen, Anja Frei, Elena Gimeno‐Santos, Nicholas S Hopkinson, Nathalie Ivanoff, Niklas Karlsson, Zafeiris Louvaris, Michael I. Polkey, Roberto Rabinovich, Mario Scuri, Maggie Tabberer, Ioannis Vogiatzis, Thierry Troosters	23
7	Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease 2018 ·American Journal of Respiratory and Critical Care Medicine ·Thierry Troosters, François Maltais, Nancy Kline Leidy, Kim Lavoie, Maria Sedeno, Wim Janssens, Judith García‐Aymerich, Damijan Eržen, (unknown), Lawrence Korducki, Alan Hamilton, Jean Bourbeau	71
8	Effect of 8 and 12 weeks' once-daily tiotropium and olodaterol, alone and combined with exercise training, on exercise endurance during walking in patients with COPD 2017 ·Pneumologie ·Thierry Troosters, Jean Bourbeau, François Maltais, (unknown), Damijan Eržen, (unknown), Lawrence Korducki, (unknown), Wim Janssens, A. Hamilton	2
9	Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design 2016 ·BMJ Open ·Thierry Troosters, Jean Bourbeau, François Maltais, Nancy Kline Leidy, Damijan Eržen, (unknown), Lawrence Korducki, Alan Hamilton	36
10	Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation 2016 ·BMJ Open ·Jean Bourbeau, Kim Lavoie, Maria Sedeno, (unknown), Damijan Eržen, Alan Hamilton, François Maltais, Thierry Troosters, Nancy Kline Leidy	20
11	Early systemic inflammatory response in mice after a single oral gavage with live Escherichia coli is evidenced by increased TNF-alpha and nitric oxide production 2011 ·Research in Veterinary Science ·Ana Nemec, Aleš Jerin, Irena Zdovc, Tomaž Büdefeld, Frank J. Μ. Verstraete, Damijan Eržen, Marjeta Šentjurc, Milan Petelin, (unknown), Zlatko Pavlica	3
12	Aerosolized clindamycin is superior to aerosolized dexamethasone or clindamycin-dexamethasone combination in the treatment of severePorphyromonas gingivalisaspiration pneumonia in an experimental murine model 2011 ·Experimental Lung Research ·Ana Nemec, Zlatko Pavlica, (unknown), Damijan Eržen, Aleksandra Milutinović, Milan Petelin	9
13	Systemic use of selective iNOS inhibitor 1400W or non-selective NOS inhibitor l-NAME differently affects systemic nitric oxide formation after oral Porphyromonas gingivalis inoculation in mice 2010 ·Archives of Oral Biology ·Ana Nemec, Zlatko Pavlica, Milan Petelin, David A. Crossley, Marjeta Šentjurc, Aleš Jerin, Damijan Eržen, Irena Zdovc, (unknown), U Skalerič	5
14	Chronic ingestion ofPorphyromonas gingivalisinduces systemic nitric oxide response in mice 2009 ·Oral Microbiology and Immunology ·A. Nemec, Zlatko Pavlica, David A. Crossley, Marjeta Šentjurc, Aleš Jerin, Damijan Eržen, Milka Vrecl, Gregor Majdič, Irena Zdovc, (unknown), U Skalerič	4
15	LACK OF SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1 AND 2 AND INTERLEUKIN-1β COMPARTMENTALIZATION IN LUNGS OF MICE AFTER A SINGLE INTRATRACHEAL INOCULATION WITH LIVEPORPHYROMONAS GINGIVALIS 2009 ·Experimental Lung Research ·Ana Nemec, Zlatko Pavlica, Alenka Nemec Svete, Damijan Eržen, David A. Crossley, Milan Petelin	6
16	Local and Systemic Up-regulation of TNFα, IL-1β and IL-6 in Mice Intratracheally Inoculated with Porphyromonas gingivalis 2008 ·Acta Veterinaria Brno ·Zlatko Pavlica, A. Nemec, (unknown), Damijan Eržen, David A. Crossley, (unknown)	2
17	Single gavage withPorphyromonas gingivalisreduces acute systemic nitric oxide response in mice 2008 ·Oral Microbiology and Immunology ·A. Nemec, Zlatko Pavlica, Marjeta Šentjurc, David A. Crossley, Aleš Jerin, Damijan Eržen, Irena Zdovc, (unknown), U Skalerič	4
18	Molecular Epidemiology of Tuberculosis in Slovenia: Results of a One-Year (2001) Nation-wide Study 2003 ·Scandinavian Journal of Infectious Diseases ·Manca Žolnir-Dovč, Mario Poljak, Damijan Eržen, Jurij Šorli	16
19	Income Level and Asthma Prevalence and Care Patterns 1997 ·American Journal of Respiratory and Critical Care Medicine ·Damijan Eržen, Keumhee C. Carrière, Natalia Dik, Cameron Mustard, Leslíe L. Roos, Jure Manfreda, Nicholas R. Anthonisen	60
20	Changes in Asthma Severity in Manitoba 1995 ·CHEST Journal ·Damijan Eržen, Leslíe L. Roos, Jure Manfreda, Nicholas R. Anthonisen	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact